Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy

Gruppo Infettivologi Penitenziari

Research output: Contribution to journalArticlepeer-review

Abstract

Background: People who are incarcerated have a significantly higher prevalence of HCV infection than the general population. Given their high-risk behavior, they represent a reservoir of HCV infection for the whole community. Methods: We evaluated all HCV-infected people who were incarcerated in 25 Italian prisons starting direct-acting antivirals (DAAs) treatment between May 2015 and October 2016. We collected information on demographic characteristics, liver disease, HCV-related aspects, anti-HCV treatment, HIV or HBV co-infection. Results: We enrolled 142 incarcerated people treated with DAAs. They were mostly Italians (93.7%) and males (98.6%). Median age was 50 years and 108/142 (76.1%) were cirrhotic patients. Prevalent genotypes were 1a (35.9%) and 3 (35.9%). Two patients were HBV co-infected, twenty-one patients (14.8%) were HIV co-infected and almost all (95.2%) received antiretroviral therapy. 118/142 (83.1%) DAAs-based regimens included sofosbuvir. Treatment completion rate was 94.4%. There were eight (5.6%) discontinuations, one (0.7%) due to an adverse reaction, one due to death (0.7%) and six (5.6%) due to release from prison. SVR12 was achieved in 90.8%. Four patients relapsed but no breakthrough occurred. Conclusions: Our study shows that in Italian penitentiary settings DAAs treatment is feasible and effective. This intervention is crucial for reducing HCV circulation with possible benefits to the general population.

Original languageEnglish
Pages (from-to)50-53
Number of pages4
JournalInternational Journal of Drug Policy
Volume59
DOIs
Publication statusPublished - Sep 1 2018

Keywords

  • Direct acting antivirals
  • Hepatitis C virus
  • Inmates
  • Prison settings

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Policy

Fingerprint Dive into the research topics of 'Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy'. Together they form a unique fingerprint.

Cite this